Body’s Own Gene Editing System Generates Leukemia Stem Cells

Inhibiting the editing enzyme may provide a new therapeutic approach for blood cancers —

Cancer stem cells are like zombies — even after a tumor is destroyed, they can keep coming back. These cells have an unlimited capacity to regenerate themselves, making more cancer stem cells and more tumors. Researchers at University of California San Diego School of Medicine have now unraveled how pre-leukemic white blood cell precursors become leukemia stem cells. The study, published June 9 in Cell Stem Cell, used human cells to define the RNA editing enzyme ADAR1’s role in leukemia, and find a way to stop it. … Read the Full Story from the UC San Diego Newsroom


Catriona H. M. Jamieson, MD, PhD

Catriona H. M. Jamieson, MD, PhD

The senior author of the study report is Catriona Jamieson, MD, PhD, Associate Professor of Medicine and Chief of the Division of Regenerative Medicine.

Dr. Jamieson is Deputy Director of the Sanford Stem Cell Clinical Center at UC San Diego Health, Director of the CIRM Alpha Stem Cell Clinic at UC San Diego School of Medicine and Director of Stem Cell Research at UC San Diego Moores Cancer Center.

UC San Diego Division of Regenerative Medicine coauthors include Sheldon Morris, MD, MPH, Data Management Lead for the UC San Diego CIRM Alpha Stem Cell Clinic; co-first authors Maria Anna Zipeto and Angela C. Court, Anil Sadarangani, Nathaniel P. Delos Santos, Larisa Balaian, Gabriel Pineda, Cayla N. Mason, Ifat Geron, Daniel J. Goff, Russell Wall, Leslie A. Crews and Qingfei Jiang.

Read the study report (UC San Diego only)

Visit the Jamieson Lab Website

Enzyme Accelerates Malignant Stem Cell Cloning in Chronic Myeloid Leukemia

An international team, headed by researchers at the University of California, San Diego School of Medicine, has identified a key enzyme in the reprogramming process that promotes malignant stem cell cloning and the growth of chronic myeloid leukemia (CML), a cancer of the blood and marrow that experts say is increasing in prevalence. … Read the full story from the UCSD Newsroom


Catriona H. M. Jamieson, MD, PhDPrincipal investigator of the study is Catriona H. M. Jamieson, MD, PhD, associate professor of medicine in the Division of Hematology-Oncology and director of stem cell research at the UC San Diego Moores Cancer Center.

Dr. Jamieson is on the steering committee for the Moores Cancer Center’s My Answer to Cancer initiative for personalized cancer therapy. She is a member of the faculty in the UCSD Biomedical Sciences Graduate Program.

Department of Medicine faculty coauthor Sheldon R. Morris, MD, MPH, an investigator at the UCSD Antiviral Research Center,is health sciences assistant clinical professor in the Division of Infectious Diseases.

Citation for the report in PNAS: Jiang Q, Crews LA, Barrett CL, Chun H-J, Court AC, Isquith JM, Zipeto MA, Goff DJ, Minden M, Sadarangani A, Rusert JM, Dao K-HT, Morris SR, Goldstein LSB, Marra MA, Kelly A. Frazer KA, Jamieson C.H.M. ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia. PNAS 2012; published ahead of print December 28, 2012, doi:10.1073/pnas.1213021110

Read the study report (free full text)

More about Dr. Jamieson and her work: